X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition of AlmataBio, Avalo acquires Phase 2-ready, AVTX-009, a humanized monoclonal antibody (IgG4) that binds to interleukin-1β, being developed for hidradenitis suppurativa.
Lead Product(s): AVTX-009
Therapeutic Area: Dermatology Product Name: AVTX-009
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: AlmataBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 27, 2024
Details:
The net proceeds will be used for the developement of AVTX-009, a humanized monoclonal antibody (IgG4) that binds to interleukin-1β, being developed for hidradenitis suppurativa.
Lead Product(s): AVTX-009
Therapeutic Area: Dermatology Product Name: AVTX-009
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Commodore Capital
Deal Size: $185.0 million Upfront Cash: $115.6 million
Deal Type: Private Placement March 27, 2024
Details:
Under the divestiture, AUG gains rights, title and interest in, assets relating to AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose). AVTX-801 is a therapeutic dose of D-galactose currently in development for the treatment of phosphoglucomutase 1 deficiency.
Lead Product(s): Alpha-D-Galactose
Therapeutic Area: Genetic Disease Product Name: AVTX-801
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AUG Therapeutics
Deal Size: $45.1 million Upfront Cash: $0.1 million
Deal Type: Divestment September 12, 2023
Details:
AVTX-002 (quisovalimab) is a fully human monoclonal antibody (mAb), directed against human LIGHT, and investigated for the treatment of patients with poorly controlled non-eosinophilic asthma
Lead Product(s): Quisovalimab
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AVTX-002
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2023
Details:
AVTX-002 is a fully human monoclonal antibody, directed against human LIGHT. AVTX-002 is currently in Phase 2 development for non-eosinophilic asthma (NEA) with proof-of-concept data in inflammatory bowel diseases (IBD) and COVID-19 acute respiratory distress syndrome (ARDS).
Lead Product(s): AVTX-002
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AVTX-002
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: SVB Securities
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 02, 2023
Details:
AVTX-002 is a fully human monoclonal antibody (mAb), directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes).
Lead Product(s): Monoclonal Antibody
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AVTX-002
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
Details:
AVTX-007 is a fully human monoclonal antibody for the treatment of Still’s Disease, including adult-onset Still’s disease (AOSD) and systemic juvenile jdiopathic Arthritis (SJIA).
Lead Product(s): AVTX-007
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AVTX-007
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: ES Therapeutics
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Agreement November 07, 2022
Details:
The active pharmaceutical ingredient (API) in AVTX-803 is L-fucose an oral formulation of L-fucose that enhances fucosylation of proteins in the absence of a functioning GDP-fucose transporter, partially restoring protein function.
Lead Product(s): L-Fucose
Therapeutic Area: Genetic Disease Product Name: AVTX-803
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2022
Details:
Under the terms of the agreement, Apollo will assume responsibility for the future development of AVTX-007 (camoteskimab), including the ongoing clinical trial. Apollo will lead future clinical development in its selected therapeutic indications.
Lead Product(s): AVTX-002
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AVTX-002
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Apollo Therapeutics
Deal Size: $89.0 million Upfront Cash: $15.0 million
Deal Type: Licensing Agreement August 01, 2022
Details:
MDGN-002 (AVTX-002) is a fully human anti-LIGHT, monoclonal antibody in development for the treatment of acute respiratory distress syndrome (ARDS), the treatment of inflammatory bowel disease (IBD) and the treatment of non-eosinophilic asthma.
Lead Product(s): AVTX-002
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: MDGN-002
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
